ACRS - アクラリス・セラピュ―ティクス (Aclaris Therapeutics Inc.) アクラリス・セラピュ―ティクス

 ACRSのチャート


 ACRSの企業情報

symbol ACRS
会社名 Aclaris Therapeutics Inc (アクラリス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アクラリス・セラピュティクス(Aclaris Therapeutics Inc.)は皮膚科学者主導のバイオ医薬品会社である。同社は皮膚科兆候の治療のために差別化された薬物の特定・開発・商業化に従事する。また、炎症性疾患、免疫学的疾患および癌を治療するためのキナーゼ阻害剤の発見・開発を行う。同社の創薬プラットフォームKINect技術は、キナーゼに焦点を当てた薬物探索エンジンである。そのKINectは、独自の化合物コレクションを統合するために計算化学を利用し、潜在的な候補者を同定して前臨床・臨床開発に進めるために高度に経験豊富な生物学者と薬化学者より協力を貰える。   アクラリス・セラピュ―ティクスは米国の専門医薬品企業。臨床段階で、皮膚疾患に対する局所用薬剤の開発、商業化に従事。主要な薬剤候補「A-101」は高濃度過酸化水素ベ―スで、脂漏性角化症や良性皮膚腫瘍の治療に利用される。同社は「A-101」の臨床試験を3件完了し、顔面や腹部の腫瘍治療に効果を上げる。本社はペンシルベニア州マルバ―ン。   Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
本社所在地 640 Lee Road Suite 200 Wayne PA 19087 USA
代表者氏名 Stephen A. Tullman スティーブン・A・Tullman
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 484-324-7933
設立年月日 41091
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 96人
url www.aclaristx.com
nasdaq_url https://www.nasdaq.com/symbol/acrs
adr_tso
EBITDA EBITDA(百万ドル) -106.29000
終値(lastsale) 13.26
時価総額(marketcap) 410803591.38
時価総額 時価総額(百万ドル) 405.53690
売上高 売上高(百万ドル) 6.47700
企業価値(EV) 企業価値(EV)(百万ドル) 241.48490
当期純利益 当期純利益(百万ドル) -104.41000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aclaris Therapeutics Inc revenues increased from $0K to $4.8M. Net loss increased from $27.4M to $61.4M. Revenues reflect Revenue increase from $0K to $1.1M. Higher net loss reflects Research and Development - gross increase of 82% to $24.1M (expense) General and Administrative - gross increase of 14% to $9.8M (expense) Stock-based Compensation in R&D increase of 38% to $3.5M (expense).

 ACRSのテクニカル分析


 ACRSのニュース

   The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street  2020/10/08 11:52:19 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) InVitae Corp (NYSE: NVTA ) Insulet Corporation (NASDAQ: PODD ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) (preannounced positive Q3 revenues) Oncorus Inc (NASDAQ: ONCR ) (debuted on Friday) Prelude Therapeutics Inc (NASDAQ: PRLD ) Pulmonx Corp (NASDAQ: LUNG ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) Stoke Therapeutics Inc (NASDAQ: STOK ) (announced decision to dose STK-001 in children and adolescents in its Phase 1/2a study for Dravet syndrome) Surface Oncology Inc (NASDAQ: SURF ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx …
   The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences  2020/10/07 11:30:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Inc (NASDAQ: PRLD ) ProPhase Labs Inc (NASDAQ: PRPH ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 6) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) (reacted to negative results for a mid-stage study of lenabasum in cystic fibrosis patients) Dyne Therapeutics Inc (NASDAQ: DYN ) Outset Medical Inc (NASDAQ: OM ) Teligent Inc (NASDAQ: TLGT ) Stocks In Focus Integra LifeSciences' Preliminary Q3 Revenues Exceed Estimate Medtech company Integra Lifesciences Holdings Corp (NASDAQ: IART ) preannounced third-quarter results, expecting revenues of $368 million to $370 million, down about 2.7%, but exceeding the company's guidance provided at …
   The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation  2020/10/06 12:24:11 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) argenx SE – ADR (NASDAQ: ARGX ) (presented positive new data from a Phase 3 trial evaluating efgartigimod in patients with generalized myasthenia gravis) Ascendis Pharma A/S (NASDAQ: ASND ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) (went public Friday) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) Cytokinetics, Inc. (NASDAQ: CYTK ) (reacted to presentations at the Heart Failure Society of America virtual meeting) Eidos Therapeutics Inc (NASDAQ: EIDX ) - announced a deal to be bought by BridgeBio Pharma Inc (NASDAQ: BBIO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) Myokardia Inc (NASDAQ: MYOK ) - announced a deal to be bought by Bristol-Myers Squibb Co (NYSE: BMY ) for $13.
   Aclaris Therapeutics to Present at Upcoming Investor Conferences  2020/09/01 20:01:00 GlobeNewswire
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on…
   Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights  2020/08/07 07:00:00 Benzinga
• First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid …
   Aclaris Therapeutics to Present at Upcoming Investor Conferences  2020/09/01 20:01:00 GlobeNewswire
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on…
   Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights  2020/08/07 07:00:00 Benzinga
• First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid …
   Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know  2020/08/06 16:30:04 Yahoo Finance
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Seborrhea Pipeline Research Monitor, 2020 Featuring Aclaris Therapeutics, Arcutis Biotherapeutics, Cutanea Life Sciences, and Vyome Therapeutics - ResearchAndMarkets.com  2020/07/24 11:14:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Seborrhea Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Seborrhea is one of the widely researched conditions during 2020 with 4 companies actively focusing on realizing pipeline's potential. Development of Seborrhea medicines is identified as integral to the strategy of the majority of companies operating in the indust
   The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold  2020/07/21 11:58:40 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) AstraZeneca plc (NYSE: AZN ) ( announced positive Phase 1/2 readout for the coronavirus vaccine it is co-developing with the Oxford University) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (reacted to positive late-stage readout for BXCK501 in treating schizophrenia and bipolar disorder) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp Inc (NASDAQ: CTSO ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Emergent Biosolutions Inc (NYSE: EBS ) Fortress Biotech (NASDAQ: FBIO ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Illumina, Inc.
   Will Aclaris Therapeutics Continue to Surge Higher?  2020/05/12 14:47:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Aclaris Therapeutics
   All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy  2020/05/08 16:00:10 Zacks Investment Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company  2020/03/20 11:44:59 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx  2020/01/10 12:13:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アクラリス・セラピュ―ティクス ACRS Aclaris Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)